The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27789138 |
355 |
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.![EBI](/images/logo_chembl.png) |
Abbvie Bioresearch Center |
27816515 |
143 |
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png) |
Icahn School of Medicine At Mount Sinai |
25462247 |
20 |
In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.![EBI](/images/logo_chembl.png) |
Fudan University |
24793884 |
151 |
Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.![EBI](/images/logo_chembl.png) |
Amgen |
24176395 |
30 |
2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.![EBI](/images/logo_chembl.png) |
Mitsubishi Tanabe Pharma |
22982525 |
32 |
Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png) |
TBA |
22944772 |
15 |
Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.![EBI](/images/logo_chembl.png) |
TBA |
22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.![EBI](/images/logo_chembl.png) |
Cellzome |
24900428 |
67 |
Structure-Based Design of Potent and Selective CK1¿ Inhibitors.![EBI](/images/logo_chembl.png) |
TBA |
23039927 |
44 |
Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.![EBI](/images/logo_chembl.png) |
Martin-Luther-University Halle-Wittenberg |
22877629 |
42 |
2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1¿) inhibitors.![EBI](/images/logo_chembl.png) |
Amgen |
22148921 |
48 |
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c![EBI](/images/logo_chembl.png) |
Cephalon |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.![EBI](/images/logo_chembl.png) |
University of Oxford |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
22136433 |
67 |
7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.![EBI](/images/logo_chembl.png) |
Ludwig-Maximilians University of Munich |
22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).![EBI](/images/logo_chembl.png) |
Ansaris |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
21080703 |
20 |
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.![EBI](/images/logo_chembl.png) |
Imperial College |
21620699 |
51 |
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.![EBI](/images/logo_chembl.png) |
Pfizer |
21035334 |
55 |
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.![EBI](/images/logo_chembl.png) |
Martin-Luther-University Halle-Wittenberg |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
20472330 |
16 |
Novel 8-arylated purines as inhibitors of glycogen synthase kinase.![EBI](/images/logo_chembl.png) |
Institut Curie |
20363627 |
56 |
Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.![EBI](/images/logo_chembl.png) |
Universit£ |
20166671 |
85 |
Selectively nonselective kinase inhibition: striking the right balance.![EBI](/images/logo_chembl.png) |
Schering-Plough |
19035792 |
85 |
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.![EBI](/images/logo_chembl.png) |
Glaxosmithkline |
18799313 |
20 |
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.![EBI](/images/logo_chembl.png) |
Università |
17166835 |
12 |
Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors.![EBI](/images/logo_chembl.png) |
Istituto Di Ricerche Di Biologia Molecolare &Quot;P. Angeletti |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
27491711 |
422 |
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.![EBI](/images/logo_chembl.png) |
Merck And |
30707835 |
18 |
Chemical Control of Mammalian Circadian Behavior through Dual Inhibition of Casein Kinase I? and ?.![EBI](/images/logo_chembl.png) |
Korea Institute of Science and Technology |
31400711 |
29 |
Small molecule modulators targeting protein kinase CK1 and CK2.![EBI](/images/logo_chembl.png) |
China Pharmaceutical University |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png) |
University of Florida |
26505898 |
123 |
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.![EBI](/images/logo_chembl.png) |
Novartis Institutes For Biomedical Research |
26509640 |
234 |
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.![EBI](/images/logo_chembl.png) |
Abbvie Bioresearch Center |
23275831 |
121 |
Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).![EBI](/images/logo_chembl.png) |
Moffitt Cancer Center |
30978288 |
113 |
A Selective and Brain Penetrant p38?MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.![EBI](/images/logo_chembl.png) |
Northwestern University |
31046271 |
21 |
Discovery of ( E)- N![EBI](/images/logo_chembl.png) |
Chinese Academy of Sciences |
30082069 |
359 |
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
28478927 |
46 |
Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.![EBI](/images/logo_chembl.png) |
Martin-Luther-University Halle-Wittenberg |
17630989 |
9 |
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.![BDB](/images/logo_bindingdb.png) |
Abbott Laboratories |